Brokerages Set Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Price Target at $12.63

Posted by Stanley Muller on Jun 7th, 2026

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX – Get Free Report) has received an average rating of “Buy” from the nine research firms that are presently covering the firm, MarketBeat.com reports. Eight analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $12.6250.

A number of brokerages have recently commented on CATX. Truist Financial set a $12.00 price target on Perspective Therapeutics in a report on Tuesday, March 17th. Piper Sandler began coverage on Perspective Therapeutics in a report on Thursday, February 19th. They issued an “overweight” rating and a $16.00 price target on the stock. B. Riley Financial boosted their price target on Perspective Therapeutics from $11.00 to $13.00 and gave the company a “buy” rating in a report on Wednesday, March 18th. UBS Group boosted their price target on Perspective Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a report on Wednesday, March 18th. Finally, BTIG Research restated a “buy” rating and issued a $14.00 price target on shares of Perspective Therapeutics in a report on Tuesday, March 17th.

Read Our Latest Stock Report on CATX

Institutional Trading of Perspective Therapeutics

A number of institutional investors have recently modified their holdings of CATX. Commodore Capital LP bought a new stake in shares of Perspective Therapeutics in the first quarter valued at about $26,424,000. Affinity Asset Advisors LLC raised its holdings in Perspective Therapeutics by 954.9% during the first quarter. Affinity Asset Advisors LLC now owns 3,164,582 shares of the company’s stock worth $13,196,000 after acquiring an additional 2,864,582 shares in the last quarter. Avidity Partners Management LP raised its holdings in Perspective Therapeutics by 88.4% during the first quarter. Avidity Partners Management LP now owns 6,049,999 shares of the company’s stock worth $25,228,000 after acquiring an additional 2,839,266 shares in the last quarter. Spruce Street Capital LP bought a new stake in Perspective Therapeutics during the first quarter worth about $10,955,000. Finally, Opaleye Management Inc. bought a new stake in Perspective Therapeutics during the fourth quarter worth about $3,257,000. 54.66% of the stock is currently owned by institutional investors.

Perspective Therapeutics Price Performance

NYSEAMERICAN:CATX opened at $3.03 on Thursday. Perspective Therapeutics has a 1 year low of $1.96 and a 1 year high of $6.16. The stock has a 50-day moving average price of $4.05 and a two-hundred day moving average price of $3.75.

Perspective Therapeutics (NYSEAMERICAN:CATX – Get Free Report) last posted its earnings results on Monday, May 11th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. The firm had revenue of $0.08 million during the quarter, compared to analysts’ expectations of $0.16 million. Perspective Therapeutics had a negative return on equity of 42.33% and a negative net margin of 17,982.69%. Research analysts expect that Perspective Therapeutics will post -1.13 earnings per share for the current fiscal year.

Perspective Therapeutics Company Profile

(Get Free Report)

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.